Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716706 | 0.87 | RXFP1 (0.51) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL21701478 | 0.85 | CYP1A2 (0.61) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL6717150 | 0.84 | MAPK1 (0.64) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL8589705 | 0.79 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2RXFP1MAPK1 | |
| SCHEMBL6633899 | 0.71 | PTPN2 (0.75) | RAB9ANPC1SMN1; SMN2PKMGFER | |
| SCHEMBL6632563 | 0.71 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL13219529 | 0.70 | KCNMA1 (0.68) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL6633552 | 0.70 | SMN1; SMN2 (1.00) | RAB9ANPC1SMN1; SMN2MAPK1TSHR | |
| SCHEMBL30587183 | 0.70 | SMN1; SMN2 (1.00) | RAB9ANPC1SMN1; SMN2MAPK1TSHR | |
| SCHEMBL7073482 | 0.70 | CES1 (0.58) | RAB9ASMN1; SMN2RXFP1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | claimed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
| US-6673788-B2 | CONTAINING 2,2,2-TRIFLUORO-1-OXOETHYL GROUPS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6673784-B1 | HALOSUBSTITUTED ACETOPHENONES AS SELECTIVE HERPESVIRUS PROTEASE INHIBITORS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | disclosed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | RAB9A 1684/4885NPC1 1523/4885SMN1; SMN2 3054/4885 |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | RAB9A 1684/4885NPC1 1523/4885SMN1; SMN2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.